News >

Gomella Gives Predictions for Prostate Cancer Advances in 2018

Gina Columbus
Published: Sunday, Mar 25, 2018

Dr. Leonard G. Gomella

Leonard G. Gomella, MD
The year ahead in the prostate cancer paradigm is expected to include an increased use of genetic testing, approximately 2 more FDA approvals, a debate between agents in the nonmetastatic castration-resistant setting, and a reversed opinion on screening, explains Leonard G. Gomella, MD.

2018 began with the FDA approval of apalutamide (Erleada) in February for patients with nonmetastatic castration-resistant prostate cancer (CRPC), which is the first FDA-approved therapy in this setting. In March, the agency granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) in the same population. If approved, Gomella predicts the decision on which agent to use first will spark a debate within the community.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x